Pfizer bows, but is not entirely out of the GLP-1 race.Bad news for Pfizer (PFE 1.19%) turned into good news for Eli Lilly (LLY 2.50%), Novo Nordisk (NVO 2.21%), and Viking Therapeutics (VKTX 8.78%) Monday morning, each of which is rising on Pfizer's latest product announcement.Early this morning, Pfizer announced it will discontinue development of its danuglipron (PF-06882961) once-a-day oral GLP-1 weight loss pill. Shares of companies will injectable GLP-1 drugs already on the market -- Eli Lilly and Novo ...

Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 10.1% to trade at $24.42 today, and traded as high as $27.09 earlier in the session. The drugmaker is on the move after Pfizer (PFE) halted the development of its weight-loss pill. Viking has two weight-loss drug candidates that have shown promising results in Phase 1 and 2 trials late last year. Sector peers Eli Lilly (LLY) and Novo Nordisk (NVO) -- two heavy hitters in the weight-loss treatment department -- are also higher today.VKTX is still down 39.3% i ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient did not experience any liver-related symptoms or side effects, a Pfizer spokesperson said in a statement. They added that the patient's liver enzymes "recovered rapidly" after they stopped taking the pill, which is an oral GLP-1 drug called danuglipron. The statement suggests that the patient's liver enzymes were ...

Core Viewpoint - Pfizer's shares have been declining for three years, but they may present a buying opportunity for long-term investors [1][2] Group 1: Impact of Tariffs - Pfizer is well-positioned to handle potential tariffs due to its significant manufacturing capacity in the U.S. [3][4] - The company operates the largest U.S.-based manufacturing network in the pharmaceutical industry, with 13 operational sites [4] - Unlike many drugmakers, Pfizer can shift manufacturing operations to the U.S. to avoid tariffs, which could lead to cost savings [5][6] Group 2: Financial Performance - Pfizer's revenue for 2024 increased by 7% year over year to $63.6 billion, with a 12% growth rate excluding contributions from its coronavirus products [8] - The company has reduced its reliance on its coronavirus products, Comirnaty and Paxlovid, which generated a combined $11.1 billion [7][8] - Pfizer's acquisition of Seagen for $43 billion has strengthened its oncology business and expanded its pipeline, which includes over 100 candidates across various therapeutic areas [9] Group 3: Valuation and Future Outlook - Pfizer's forward price-to-earnings (P/E) ratio is 7.6, significantly lower than the healthcare industry's average of 15.8, indicating that the stock is undervalued [12] - The company is focused on launching new products to establish a strong foundation for future growth [10][11]

Pfizer (PFE) ended the recent trading session at $21.91, demonstrating a +1.48% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 1.81%. On the other hand, the Dow registered a gain of 1.56%, and the technology-centric Nasdaq increased by 2.06%.The drugmaker's stock has dropped by 15.66% in the past month, falling short of the Medical sector's loss of 12.01% and the S&P 500's loss of 6.14%.The investment community will be paying close attention to the earnings perfor ...

Pfizer’s (PFE) stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49Though the stock has seen ups and downs in the past year, the latest price decline is largely due to the global uncertainty caused by the tariff war. With the Trump administration imposing sweeping tariffs, fears of a global recession resulted in a stock market rout worldwide. Though pharmaceuticals have been exempted from tariffs this time around, they could well be Trump’s target in the next roun ...

Group 1 - Pfizer Inc. is facing significant challenges, particularly low investor sentiment and a declining stock price [1] - The company is categorized as a healthcare giant and is publicly traded on the NYSE under the ticker symbol PFE [1] Group 2 - The article does not provide specific financial metrics or performance data related to Pfizer Inc. [1]

Analyst's Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to fi ...